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FOR A NUMBER of years WR-2721 or
S-2-(3-aminopropylamino) ethylphosphor-
othioic acid has been being considered as a
potential means of selectively reducing
radiation injury to normal tissues, while
leaving solid tumours to suffer the full
effects of the exposure (Yuhas, 1980a).
This drug is readily absorbed by most
normal tissues (Washburn et al., 1974) and
can increase their radiation resistance by
factors of up to 3. By contrast solid
tumours absorb barely detectable quanti-
ties of the drug, and are therefore not
radioprotected (Yuhas, 1980a). This differ-
ential absorption and protection was
originally assumed to be the product of
differences in normal and tumour tissue
vascularity, but more recently it has been
shown that normal tissues (with the ex-
ception of the CNS) actively concentrate
WR-2721 against a gradient, whereas
solid tuimours passively absorb it or, at
most, concentrate it at a far reduced rate
(Yuhas, 1980b).
Whatever the final resolution of the
mechanisms involved, it is now apparent
that WR-2721, and other drugs like it,
might have a more general application in
cancer therapy than we originally en-
visaged (Yuhas & Storer, 1969). WVe would
like to expand our original proposal
(Yuhas & Storer, 1969) to state that WR-
2721 should selectively protect normal
tissues (except the CNS) against any form
of cancer therapy which involves either
radiation or alkylating agents or their
combination. We have shown recently
that injection of WR-2721 30 min before
A cepted 24 Jatiav I v980()
injection of nitrogen mustard (HN2)
increases the resistance of mice to HN2-
induced mortality by a factor of 2-0, but
does not alter the sensitivity of the Line 1
lung carcinoma they bear to HN2-induced
growth delay (Yuhas, 1l979a). The same
pattern was observed with another alkyl-
ating agent, cis-platinum: resistance to
cis-platinum-induced nephrotoxicity was
increased bv a factor of 17, but none of
the 3 solid tumours studied showed
altered resistance to cis-platinum follow-
ing WR-2721 pre-treatment (Yuhas &
('ulo, 1980). Since similar patterns have
been obtained with cyclophosphamide
(Yuhas, 1980b) and L-phenylalanine mus-
tard (Yuhas, unpublished observations) it
would appear that WR-2721 could prove
to be an effective adjunct to alkylating-
agent chemotherapy.
The point ofthe present argumeint is not
merely whether WR-2721 would be
effective in radiotherapy or alkylating-
agent chemotherapy, but whether it
would be effective in any type of therapy
involving one and/or the other treatment
modality. To test the possibility that
AVR-2721 could selectively protect normal
tissues against the toxic interaction of
radiation and alkylating agents, we trans-
planted the 3M2N mammary carcinoma
(5 x 106 cells) into the right hind leg of
6 groups of 8 female Fisher 344 rats each
70 + 5 days old, and initiated therapy
when their tumours had grown to - 9 mm,
i.e. 14 days later. Rats were given an
injection of saline (0.75 ml) or WR-2721
(200 mg/kg; Sample AN) in an equivalentWR-2721 IN CANCER THERAPY
volume, followed 30 min later by X-rays
(0 or 2500 rad) and/or cis-dichlorodiam-
mineplatinum (Cis-Plat, Bristol Labora-
tories, Syracuse, New York). The 25OkVp
X-rays were delivered at a rate of 164 rad/
min to the tumour-bearing leg, the re-
mainder of the body being shielded by
lead. Immediately after exposure, the rats
were given a single i.p. injection of 0 or
5 mg/kg of Cis-Plat (0.005 ml/g body wt).
For the next 45 days, the skin reactions
were scored 3 x weekly, and at the same
time the tumours were sized with Vernier
calipers. Skin response was expressed as
the peak skin reaction during the first, 45
days after irradiation (usually Days 20-
25), whilst tumiour response is expressed as
the treatment-induced delay in time re-
quired for the tumours to grow 4 mm
beyond their size at the time oftreatment.
As shown in the Table, in the absence of
WR-2721 pre-treatment, the combination
ofradiation (2500 rad) and Cis-Plat (5 mg/
kg) shows greater than additive injury to
the tumour, but unfortunately the same is
observed in the skin. However, if the rats
xvere pre-treated with WR-2721 (200 mg/
kg), this toxic interaction is eradicated in
the skin, but remains fully expressed in
the tumour (Table). Work currently in
progress in our laboratory indicates that
similar results will be obtained with other
more critical normal tissues, such as the
kidney.
In the experiment described above,
WR-2721 is effective against both arms of
the therapy, but this does not have to be
the case for this approach to be effective.
Even if we assume that WR-2721 will not
alter hyperthermic injury, it should pre-
vent synergistic interactions of radiation
and hyperthermia in normal tissues,
merely by reducing the radiation-injury
component. We do not know what effect
hyperthermia would have on the distribu-
tion and metabolism of WR-2721, but this
potential problem could be circumvented
by giving WR-2721, radiation, and then
hyperthermia, i.e. W\R-2721 will have per-
formed its ftunction before the heat was
applied.
TABLE.-EffeCtS of Irx-2721 pre-treatrnent
(200 mg/kg, i.p.) on the interaction of
X-rays (2500 rad)andcis-platinum, (5 mg/
kg) in producing skin and tumour injury
in Fisher 344 rats bearing the 3M2N
mantmmary carcinonma
Treatment *
Cis-Platillum
Radiation
Rad. + Cis-Plat.
WAR-2721 + Cis-Plat.
WVRR-272 1 +Radl.
WRR-2721 + Rad. + (is-Plat.
Tumour
growth
Peak skin delay
injuryt (days)+
0 6-1+052
2-3+0-31 4-1+0-23
40 15-1+097
o) 6 1 + 0-81
0 50+077
0-76+0-15 14-2+0-46
* WVR-2721 (200 mg/kg) giv-ein i.p. 30 mii before
radiation and/or Cis-Plat; Cis-Plat given as an i.p.
injection alone or xrithin 5 min after radiation or
30 min after WR-2721.
t l =erythema; 2= (iry (lesquamation; 3 = moist
dlesquaamation; an(l 4= ulceration.
t Delay in time required by treate(l 3M2N
tumours to grow 4 mm beyond the size at the time
of treatment.
As a last point, combinations of WR-
2721 and non-conventional radiations
may prove more effective than either
approach alone, because each is able to
compensate for the others' deficiencies.
If a situation is considered in which both
the spinal cord and the tissues immedi-
ately adjacent to the tumour are dose-
limiting, the effectiveness of WR-2721 in
improving the treatment of this tumour
would be limited by cord tolerance
because WR-2721 does not protect the
spinal cord (Yuhas, 1979b). Similarly, the
effectiveness of pions would be limited by
the radiosensitivity of the immediately
adjacent normal tissues which would have
to be included in the peak treatment
volume. The combination ofWR-2721 and
pions, however, would not suffer excess-
ively from either limitation, because one
could reduce damage to the spinal cord by
placing it in the plateau region of the pion
depth-dose curve and reduce radiosensi-
tivity of the tissues immediately adjacent
to the tumour with WR-2721.
In summary, this approach of reducing
normal tissue toxicity would appear to
have a more general application than we
originally proposed (Yuhas & Storer,
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1969). Although WR-2721 is well tolerated
by patients (Kligerman et al., 1980) and
appears to be radioprotective in them
(Sugahara & Tanaka, 1980) it should not
be considered the final solution to this
problem. There still exists much room for
drug improvement, both qualitatively and
quantitatively.
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